{ "instance": { "ara-20200630.htm": { "axisCustom": 0, "axisStandard": 32, "contextCount": 263, "dts": { "calculationLink": { "local": [ "ara-20200630_cal.xml" ] }, "definitionLink": { "local": [ "ara-20200630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "ara-20200630.htm" ] }, "labelLink": { "local": [ "ara-20200630_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ara-20200630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "ara-20200630.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 649, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 14, "http://www.americanrenal.com/20200630": 2, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 21 }, "keyCustom": 90, "keyStandard": 397, "memberCustom": 35, "memberStandard": 44, "nsprefix": "ara", "nsuri": "http://www.americanrenal.com/20200630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.americanrenal.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107103 - Disclosure - ASSETS HELD FOR SALE", "role": "http://www.americanrenal.com/role/ASSETSHELDFORSALE", "shortName": "ASSETS HELD FOR SALE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111104 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116105 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "role": "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119106 - Disclosure - VARIABLE INTEREST ENTITIES", "role": "http://www.americanrenal.com/role/VARIABLEINTERESTENTITIES", "shortName": "VARIABLE INTEREST ENTITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "ara:TemporaryEquityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121107 - Disclosure - NONCONTROLLING INTERESTS SUBJECT TO PUT PROVISIONS", "role": "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONS", "shortName": "NONCONTROLLING INTERESTS SUBJECT TO PUT PROVISIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "ara:TemporaryEquityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124108 - Disclosure - DEBT", "role": "http://www.americanrenal.com/role/DEBT", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129109 - Disclosure - LEASES", "role": "http://www.americanrenal.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137110 - Disclosure - INCOME TAXES", "role": "http://www.americanrenal.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139111 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146112 - Disclosure - EARNINGS (LOSS) PER SHARE", "role": "http://www.americanrenal.com/role/EARNINGSLOSSPERSHARE", "shortName": "EARNINGS (LOSS) PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149113 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2151114 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.americanrenal.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2153115 - Disclosure - CERTAIN LEGAL AND OTHER MATTERS", "role": "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERS", "shortName": "CERTAIN LEGAL AND OTHER MATTERS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "ara:ChangesInOwnershipInterestInConsolidatedSubsidiariesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2155116 - Disclosure - CHANGES IN OWNERSHIP INTEREST IN CONSOLIDATED SUBSIDIARIES", "role": "http://www.americanrenal.com/role/CHANGESINOWNERSHIPINTERESTINCONSOLIDATEDSUBSIDIARIES", "shortName": "CHANGES IN OWNERSHIP INTEREST IN CONSOLIDATED SUBSIDIARIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "ara:ChangesInOwnershipInterestInConsolidatedSubsidiariesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2158117 - Disclosure - SUBSEQUENT EVENTS", "role": "http://www.americanrenal.com/role/SUBSEQUENTEVENTS", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - BASIS OF PRESENTATION, ORGANIZATION AND RECENT EVENTS (Policies)", "role": "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSPolicies", "shortName": "BASIS OF PRESENTATION, ORGANIZATION AND RECENT EVENTS (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - REVENUE (Tables)", "role": "http://www.americanrenal.com/role/REVENUETables", "shortName": "REVENUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308302 - Disclosure - ASSETS HELD FOR SALE (Tables)", "role": "http://www.americanrenal.com/role/ASSETSHELDFORSALETables", "shortName": "ASSETS HELD FOR SALE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312303 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "ara:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317304 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "role": "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "ara:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322305 - Disclosure - NONCONTROLLING INTERESTS SUBJECT TO PUT PROVISIONS (Tables)", "role": "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSTables", "shortName": "NONCONTROLLING INTERESTS SUBJECT TO PUT PROVISIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325306 - Disclosure - DEBT (Tables)", "role": "http://www.americanrenal.com/role/DEBTTables", "shortName": "DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330307 - Disclosure - LEASES (Tables)", "role": "http://www.americanrenal.com/role/LEASESTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340308 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2347309 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)", "role": "http://www.americanrenal.com/role/EARNINGSLOSSPERSHARETables", "shortName": "EARNINGS (LOSS) PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2356310 - Disclosure - CHANGES IN OWNERSHIP INTEREST IN CONSOLIDATED SUBSIDIARIES (Tables)", "role": "http://www.americanrenal.com/role/CHANGESINOWNERSHIPINTERESTINCONSOLIDATEDSUBSIDIARIESTables", "shortName": "CHANGES IN OWNERSHIP INTEREST IN CONSOLIDATED SUBSIDIARIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "ara:NumberOfDialysisClinicsOwnedAndOperated", "reportCount": 1, "unique": true, "unitRef": "dialysisclinic", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - BASIS OF PRESENTATION, ORGANIZATION AND RECENT EVENTS (Details)", "role": "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails", "shortName": "BASIS OF PRESENTATION, ORGANIZATION AND RECENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "ara:NumberOfDialysisClinicsOwnedAndOperated", "reportCount": 1, "unique": true, "unitRef": "dialysisclinic", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "ara:NumberofPerformanceObligations", "reportCount": 1, "unique": true, "unitRef": "performance_obligation", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - REVENUE (Details)", "role": "http://www.americanrenal.com/role/REVENUEDetails", "shortName": "REVENUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "ara:NumberofPerformanceObligations", "reportCount": 1, "unique": true, "unitRef": "performance_obligation", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - ASSETS HELD FOR SALE - Narrative (Details)", "role": "http://www.americanrenal.com/role/ASSETSHELDFORSALENarrativeDetails", "shortName": "ASSETS HELD FOR SALE - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i1306b5c4177c457ea07e1f5b86ee15a6_D20200401-20200630", "decimals": "-3", "lang": "en-US", "name": "ara:DisposalGroupIncludingDiscontinuedOperationValuationAllowanceIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - ASSETS HELD FOR SALE - Schedule of assets and liabilities held for sale (Details)", "role": "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails", "shortName": "ASSETS HELD FOR SALE - Schedule of assets and liabilities held for sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i15eb0707135c4c2bbe4f6d5d037e2bd5_I20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of fair values (Details)", "role": "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails", "shortName": "FAIR VALUE MEASUREMENTS - Schedule of fair values (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i7485e689330e43008899880868caa942_I20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "id7b5311ac66d4042a7701c1097364633_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - FAIR VALUE MEASUREMENTS - Fair value rollforward for tax receivable agreement liability (Details)", "role": "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSFairvaluerollforwardfortaxreceivableagreementliabilityDetails", "shortName": "FAIR VALUE MEASUREMENTS - Fair value rollforward for tax receivable agreement liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "id7b5311ac66d4042a7701c1097364633_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415407 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details)", "role": "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "shortName": "FAIR VALUE MEASUREMENTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "iecf94ae5d5874223922868e41afa771d_I20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ara:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418408 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "role": "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ara:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420409 - Disclosure - VARIABLE INTEREST ENTITIES (Details)", "role": "http://www.americanrenal.com/role/VARIABLEINTERESTENTITIESDetails", "shortName": "VARIABLE INTEREST ENTITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "if7b2fe846db34812993c2bc9c0cfbe7b_I20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "id7b5311ac66d4042a7701c1097364633_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423410 - Disclosure - NONCONTROLLING INTERESTS SUBJECT TO PUT PROVISIONS (Details)", "role": "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails", "shortName": "NONCONTROLLING INTERESTS SUBJECT TO PUT PROVISIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "id7b5311ac66d4042a7701c1097364633_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426411 - Disclosure - DEBT - Schedule of long-term debt (Details)", "role": "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails", "shortName": "DEBT - Schedule of long-term debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "lang": "en-US", "name": "ara:LongtermDebtGrossAndLeaseObligationGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427412 - Disclosure - DEBT - Scheduled maturities of long-term debt (Details)", "role": "http://www.americanrenal.com/role/DEBTScheduledmaturitiesoflongtermdebtDetails", "shortName": "DEBT - Scheduled maturities of long-term debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428413 - Disclosure - DEBT - Narrative (Details)", "role": "http://www.americanrenal.com/role/DEBTNarrativeDetails", "shortName": "DEBT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i6b1d7ea15b884424894399fd731e69b8_D20200401-20200630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431414 - Disclosure - LEASES - Narrative (Details)", "role": "http://www.americanrenal.com/role/LEASESNarrativeDetails", "shortName": "LEASES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)", "role": "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432415 - Disclosure - LEASES - Lease cost (Details)", "role": "http://www.americanrenal.com/role/LEASESLeasecostDetails", "shortName": "LEASES - Lease cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433416 - Disclosure - LEASES - Supplemental cash flow related to leases (Details)", "role": "http://www.americanrenal.com/role/LEASESSupplementalcashflowrelatedtoleasesDetails", "shortName": "LEASES - Supplemental cash flow related to leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434417 - Disclosure - LEASES - Supplemental balance sheet related to leases (Details)", "role": "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails", "shortName": "LEASES - Supplemental balance sheet related to leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ara:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435418 - Disclosure - LEASES - Future Minimum Lease Payments Under Noncancelable Leases - For Period Ending June 30, 2020 (Details)", "role": "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details", "shortName": "LEASES - Future Minimum Lease Payments Under Noncancelable Leases - For Period Ending June 30, 2020 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436419 - Disclosure - LEASES - Future Minimum Lease Payments Under Noncancelable Leases - For Period Ending December 31, 2019 (Details)", "role": "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "shortName": "LEASES - Future Minimum Lease Payments Under Noncancelable Leases - For Period Ending December 31, 2019 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "id7b5311ac66d4042a7701c1097364633_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438420 - Disclosure - INCOME TAXES (Details)", "role": "http://www.americanrenal.com/role/INCOMETAXESDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441421 - Disclosure - STOCK-BASED COMPENSATION - Schedule of expense (Details)", "role": "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONScheduleofexpenseDetails", "shortName": "STOCK-BASED COMPENSATION - Schedule of expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i1c163f684510461d9bae8e711546ad4d_D20160426-20160426", "decimals": "INF", "first": true, "lang": "en-US", "name": "ara:DividendsCashPerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442422 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "role": "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i1c163f684510461d9bae8e711546ad4d_D20160426-20160426", "decimals": "INF", "first": true, "lang": "en-US", "name": "ara:DividendsCashPerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i532496ba03e3463d9b46f31b8151f500_D20200101-20200630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443423 - Disclosure - STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION - Assumptions used for options granted (Details)", "role": "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONSTOCKBASEDCOMPENSATIONAssumptionsusedforoptionsgrantedDetails", "shortName": "STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION - Assumptions used for options granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i532496ba03e3463d9b46f31b8151f500_D20200101-20200630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i77fcaa071dd14dd58906325364d4ab65_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444424 - Disclosure - STOCK-BASED COMPENSATION - Option activity (Details)", "role": "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails", "shortName": "STOCK-BASED COMPENSATION - Option activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i77fcaa071dd14dd58906325364d4ab65_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "id77d9da19a54400e85d55b0666cc435e_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statement of Changes in Equity", "role": "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity", "shortName": "Condensed Consolidated Statement of Changes in Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "id77d9da19a54400e85d55b0666cc435e_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ibe4fc8ba34814be3bf517a59828fd95d_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445425 - Disclosure - STOCK-BASED COMPENSATION - Restricted stock awards (Details)", "role": "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails", "shortName": "STOCK-BASED COMPENSATION - Restricted stock awards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "id02826cd415c48dca68e24c1e77835dc_D20200101-20200630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448426 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)", "role": "http://www.americanrenal.com/role/EARNINGSLOSSPERSHAREDetails", "shortName": "EARNINGS (LOSS) PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NetIncomeLossAttributableToParentDiluted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-5", "first": true, "lang": "en-US", "name": "ara:NotesPayableCurrentAndNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450427 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "role": "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i2abb2fb41bca42f491b7b0f2a8aa8302_D20160420-20160420", "decimals": "-3", "lang": "en-US", "name": "ara:IncomeTaxReceivableAgreementLiabilityTotal", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i7a79b76444ae49e89aadef789f2f9c7a_I20160426", "decimals": "INF", "first": true, "lang": "en-US", "name": "ara:PercentageTaxSavingsPayableToStockholders", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452428 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.americanrenal.com/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "ib3959d330f874130bb97988606e4978a_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454429 - Disclosure - CERTAIN LEGAL AND OTHER MATTERS (Details)", "role": "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails", "shortName": "CERTAIN LEGAL AND OTHER MATTERS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i9b8e505c30eb41dfa6902ddeb9efcdf4_D20180801-20180801", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457430 - Disclosure - CHANGES IN OWNERSHIP INTEREST IN CONSOLIDATED SUBSIDIARIES (Details)", "role": "http://www.americanrenal.com/role/CHANGESINOWNERSHIPINTERESTINCONSOLIDATEDSUBSIDIARIESDetails", "shortName": "CHANGES IN OWNERSHIP INTEREST IN CONSOLIDATED SUBSIDIARIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i841594087c614ba99762ff6845c25902_D20200401-20200630", "decimals": "-3", "lang": "en-US", "name": "ara:NoncontrollingInterestIncreaseDecreaseFromSaleOfParentEquityInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i06a018dad3f04971a8beb67ac7ca3743_D20200803-20200803", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459431 - Disclosure - SUBSEQUENT EVENTS (Details)", "role": "http://www.americanrenal.com/role/SUBSEQUENTEVENTSDetails", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i06a018dad3f04971a8beb67ac7ca3743_D20200803-20200803", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - BASIS OF PRESENTATION, ORGANIZATION AND RECENT EVENTS", "role": "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTS", "shortName": "BASIS OF PRESENTATION, ORGANIZATION AND RECENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104102 - Disclosure - REVENUE", "role": "http://www.americanrenal.com/role/REVENUE", "shortName": "REVENUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ara-20200630.htm", "contextRef": "i40f2303eb8ea4dcaad1556c63555e37f_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 80, "tag": { "ara_ARAARAOpCoAndARMvsUnitedHealthGroupInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ARA, ARA OpCo And ARM vs UnitedHealth Group Inc. [Member]", "label": "ARA, ARA OpCo And ARM vs UnitedHealth Group Inc. [Member]", "terseLabel": "ARA, ARA OpCo And ARM vs UnitedHealth Group Inc." } } }, "localname": "ARAARAOpCoAndARMvsUnitedHealthGroupInc.Member", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "domainItemType" }, "ara_AccruedExpenseandOtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accrued Expense and Other Current Liabilities [Member]", "label": "Accrued Expense and Other Current Liabilities [Member]", "terseLabel": "Accrued expense and other current liabilities" } } }, "localname": "AccruedExpenseandOtherCurrentLiabilitiesMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "domainItemType" }, "ara_AdjustmentsToAdditionalPaidinCapitalRelatedToCashDividendEquivalentsAccruedOnShareBasedPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjustments To Additional Paid in Capital, Related To Cash Dividend Equivalents Accrued On Share-Based Payments", "label": "Adjustments To Additional Paid in Capital, Related To Cash Dividend Equivalents Accrued On Share-Based Payments", "terseLabel": "Cash dividend equivalents accrued on share-based payments" } } }, "localname": "AdjustmentsToAdditionalPaidinCapitalRelatedToCashDividendEquivalentsAccruedOnShareBasedPayments", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "ara_AgreementsWithCertainClinicsToProvideForVariousFacilityBuildOutsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agreements With Certain Clinics To Provide For Various Facility Build Outs", "label": "Agreements With Certain Clinics To Provide For Various Facility Build Outs [Member]", "terseLabel": "Agreements With Certain Clinics To Provide For Various Facility Build Outs" } } }, "localname": "AgreementsWithCertainClinicsToProvideForVariousFacilityBuildOutsMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "ara_AliVandevarEtAl.V.AmericanRenalAssociatesHoldingsInc.EtAl.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ali Vandevar, Et Al. V. American Renal Associates Holdings Inc., Et Al. [Member]", "label": "Ali Vandevar, Et Al. V. American Renal Associates Holdings Inc., Et Al. [Member]", "terseLabel": "Ali Vandevar, et al. v. American Renal Associates Holdings Inc., et al." } } }, "localname": "AliVandevarEtAl.V.AmericanRenalAssociatesHoldingsInc.EtAl.Member", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "domainItemType" }, "ara_AlternateBaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alternate Base Rate [Member]", "label": "Alternate Base Rate [Member]", "terseLabel": "ABR rate" } } }, "localname": "AlternateBaseRateMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "ara_AlternateBaseRateOrLondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alternate Base Rate Or London Interbank Offered Rate (LIBOR) [Member]", "label": "Alternate Base Rate Or London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "Alternate Base Rate Or London Interbank Offered Rate (LIBOR)" } } }, "localname": "AlternateBaseRateOrLondonInterbankOfferedRateLIBORMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "ara_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Supplemental balance sheet information related to leases" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "ara_COVID19Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "COVID-19", "label": "COVID-19 [Member]", "terseLabel": "COVID-19" } } }, "localname": "COVID19Member", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "ara_CashFlowLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Flow, Lessee [Abstract]", "label": "Cash Flow, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowLesseeAbstract", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalcashflowrelatedtoleasesDetails" ], "xbrltype": "stringItemType" }, "ara_CertainClinicsInPennsylvaniaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Certain Clinics In Pennsylvania", "label": "Certain Clinics In Pennsylvania [Member]", "terseLabel": "Certain Clinics In Pennsylvania" } } }, "localname": "CertainClinicsInPennsylvaniaMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "ara_CertainClinicsInPennsylvaniaOhioAndNewJerseyAndOtherPropertyAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Certain Clinics In Pennsylvania, Ohio, And New Jersey And Other Property And Equipment [Member]", "label": "Certain Clinics In Pennsylvania, Ohio, And New Jersey And Other Property And Equipment [Member]", "terseLabel": "Certain Clinics In Pennsylvania, Ohio, and New Jersey and Other Property and Equipment" } } }, "localname": "CertainClinicsInPennsylvaniaOhioAndNewJerseyAndOtherPropertyAndEquipmentMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALENarrativeDetails", "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails" ], "xbrltype": "domainItemType" }, "ara_ChangesInOwnershipInterestInConsolidatedSubsidiariesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Changes In Ownership Interest In Consolidated Subsidiaries [Text Block]", "label": "Changes In Ownership Interest In Consolidated Subsidiaries [Text Block]", "terseLabel": "CHANGES IN OWNERSHIP INTEREST IN CONSOLIDATED SUBSIDIARIES" } } }, "localname": "ChangesInOwnershipInterestInConsolidatedSubsidiariesTextBlock", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CHANGESINOWNERSHIPINTERESTINCONSOLIDATEDSUBSIDIARIES" ], "xbrltype": "textBlockItemType" }, "ara_CommercialAndOtherRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commercial And Other Revenue [Member]", "label": "Commercial And Other Revenue [Member]", "terseLabel": "Commercial and other" } } }, "localname": "CommercialAndOtherRevenueMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "ara_CreditAgreement2017FirstAmendmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Credit Agreement 2017, First Amendment [Member]", "label": "Credit Agreement 2017, First Amendment [Member]", "terseLabel": "Credit Agreement 2017, First Amendment" } } }, "localname": "CreditAgreement2017FirstAmendmentMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "ara_CreditAgreement2017Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Credit Agreement 2017 [Member]", "label": "Credit Agreement 2017 [Member]", "terseLabel": "2017 Credit Agreement" } } }, "localname": "CreditAgreement2017Member", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "domainItemType" }, "ara_DebtInstrumentBasisSpreadOnVariableRateIncrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Basis Spread On Variable Rate, Increase", "label": "Debt Instrument, Basis Spread On Variable Rate, Increase", "terseLabel": "Applicable margin, increase" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRateIncrease", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "ara_DebtInstrumentCovenantNetLeverageRatioMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant, Net Leverage Ratio, Maximum", "label": "Debt Instrument, Covenant, Net Leverage Ratio, Maximum", "terseLabel": "Financial covenant, net leverage ratio, maximum" } } }, "localname": "DebtInstrumentCovenantNetLeverageRatioMaximum", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "pureItemType" }, "ara_DebtInstrumentDebtDefaultFeeAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Debt Default, Fee Amount", "label": "Debt Instrument, Debt Default, Fee Amount", "terseLabel": "Fees related to debt amendment" } } }, "localname": "DebtInstrumentDebtDefaultFeeAmount", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ara_DebtInstrumentRequiredPrepayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Required Prepayment", "label": "Debt Instrument, Required Prepayment", "terseLabel": "Required prepayment" } } }, "localname": "DebtInstrumentRequiredPrepayment", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ara_DepreciationAmortizationAndImpairment": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Depreciation, Amortization And Impairment", "label": "Depreciation, Amortization And Impairment", "terseLabel": "Depreciation, amortization and impairment" } } }, "localname": "DepreciationAmortizationAndImpairment", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "ara_DisposalGroupIncludingDiscontinuedOperationFinanceLeaseLiability": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Finance Lease Liability", "label": "Disposal Group, Including Discontinued Operation, Finance Lease Liability", "terseLabel": "Present value of lease liabilities held for sale" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationFinanceLeaseLiability", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "ara_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 }, "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Liability", "label": "Disposal Group, Including Discontinued Operation, Operating Lease Liability", "terseLabel": "Operating lease liabilities", "verboseLabel": "Present value of lease liabilities held for sale" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiability", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "ara_DisposalGroupIncludingDiscontinuedOperationValuationAllowance": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails": { "order": 6.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Valuation Allowance", "label": "Disposal Group, Including Discontinued Operation, Valuation Allowance", "negatedTerseLabel": "Valuation allowance on disposal group" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationValuationAllowance", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails" ], "xbrltype": "monetaryItemType" }, "ara_DisposalGroupIncludingDiscontinuedOperationValuationAllowanceIncreaseDecrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Valuation Allowance, Increase (Decrease)", "label": "Disposal Group, Including Discontinued Operation, Valuation Allowance, Increase (Decrease)", "terseLabel": "Increase (decrease) in valuation allowance" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationValuationAllowanceIncreaseDecrease", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ara_DividendsCashPerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash (in dollars per share).", "label": "Dividends Cash Per Share", "terseLabel": "Cash dividend (in USD per share)" } } }, "localname": "DividendsCashPerShare", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "perShareItemType" }, "ara_EquitableAdjustmentCashDividendEquivalentPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Dividend equivalent payments on certain stock options.", "label": "Equitable Adjustment Cash Dividend Equivalent Payment", "terseLabel": "Equitable adjustments in the form of cash dividend equivalent payments" } } }, "localname": "EquitableAdjustmentCashDividendEquivalentPayment", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ara_EquitableAdjustmentCashDividendEquivalentPaymentPerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents dividend equivalent payments on certain stock options per share amount.", "label": "Equitable Adjustment Cash Dividend Equivalent Payment Per Share", "terseLabel": "Equivalent adjustments in the form of cash dividend equivalent payments (in USD per share)" } } }, "localname": "EquitableAdjustmentCashDividendEquivalentPaymentPerShare", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "perShareItemType" }, "ara_EquityMethodInvestmentOwnershipParentPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investor accounted for under the equity method of accounting.", "label": "Equity Method Investment Ownership Parent Percentage", "terseLabel": "Percentage ownership of parent" } } }, "localname": "EquityMethodInvestmentOwnershipParentPercentage", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "ara_FacilitySpaceToNephrologistPartnersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facility Space To Nephrologist Partners [Member]", "label": "Facility Space To Nephrologist Partners [Member]", "terseLabel": "Facility Space to Nephrologist Partners" } } }, "localname": "FacilitySpaceToNephrologistPartnersMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "ara_FacilitySpaceToNoncontrollingInterestMembersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facility Space To Noncontrolling Interest Members [Member]", "label": "Facility Space To Noncontrolling Interest Members [Member]", "terseLabel": "Facility Space to Noncontrolling Interest Members" } } }, "localname": "FacilitySpaceToNoncontrollingInterestMembersMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "ara_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityOptionsExercisedandDividendEquivalentPaymentVesting": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Options Exercised and Dividend Equivalent Payment Vesting", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Options Exercised and Dividend Equivalent Payment Vesting", "negatedTerseLabel": "Options exercised and dividend equivalent payment vesting" } } }, "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityOptionsExercisedandDividendEquivalentPaymentVesting", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSFairvaluerollforwardfortaxreceivableagreementliabilityDetails" ], "xbrltype": "monetaryItemType" }, "ara_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance Lease Assets And Liabilities, Lessee [Abstract]", "label": "Finance Lease Assets And Liabilities, Lessee [Abstract]", "terseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseAssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "stringItemType" }, "ara_FinanceLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease, Liability, To Be Paid, After Year Four", "label": "Finance Lease, Liability, To Be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "ara_FinancingTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financing Transactions [Member]", "label": "Financing Transactions [Member]", "terseLabel": "Financing transactions" } } }, "localname": "FinancingTransactionsMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "ara_FirstLienCreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Relates to the First Lien Credit Agreement.", "label": "First Lien Credit Agreement [Member]", "verboseLabel": "First Lien Credit Agreement" } } }, "localname": "FirstLienCreditAgreementMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "ara_FirstLienCreditAgreementSecondAmendmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Relates to the First Lien Credit Agreement, second amendment", "label": "First Lien Credit Agreement, Second Amendment [Member]", "terseLabel": "First Lien Credit Agreement, Second Amendment" } } }, "localname": "FirstLienCreditAgreementSecondAmendmentMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "ara_GrantFundsEscrowLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Grant Funds Escrow Liability, Current", "label": "Grant Funds Escrow Liability, Current", "terseLabel": "Grant funds escrow" } } }, "localname": "GrantFundsEscrowLiabilityCurrent", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "ara_HealthCareOrganizationPatientServiceRevenueEstimate": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Health Care Organization Patient Service Revenue Estimate", "label": "Health Care Organization Patient Service Revenue Estimate", "terseLabel": "Amounts pending approval from third-party payors associated with Medicare recovery claims" } } }, "localname": "HealthCareOrganizationPatientServiceRevenueEstimate", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "monetaryItemType" }, "ara_IncomeTaxExpenseBenefitCARESAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Income Tax Expense (Benefit), CARES Act", "label": "Income Tax Expense (Benefit), CARES Act", "negatedLabel": "Income tax benefit, CARES Act" } } }, "localname": "IncomeTaxExpenseBenefitCARESAct", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "ara_IncomeTaxReceivableAgreementLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Income Tax Receivable Agreement Liability", "label": "Income Tax Receivable Agreement Liability", "terseLabel": "Accrued income tax receivable agreement liability" } } }, "localname": "IncomeTaxReceivableAgreementLiability", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "ara_IncomeTaxReceivableAgreementLiabilityCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Income tax receivable agreement liability current", "label": "Income Tax Receivable Agreement Liability Current", "verboseLabel": "Tax receivable agreement liability, current" } } }, "localname": "IncomeTaxReceivableAgreementLiabilityCurrent", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "ara_IncomeTaxReceivableAgreementLiabilityTotal": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Income tax receivable agreement liability total", "label": "Income Tax Receivable Agreement Liability Total", "terseLabel": "Income tax receivable agreement liability total" } } }, "localname": "IncomeTaxReceivableAgreementLiabilityTotal", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "ara_IncomeTaxReceivableAgreementPayable": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payable under tax receivable agreement noncurrent.", "label": "Income Tax Receivable Agreement Payable", "terseLabel": "Income tax receivable agreement payable" } } }, "localname": "IncomeTaxReceivableAgreementPayable", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ara_IncomeTaxReceivableAgreementPayableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing income tax receivable agreement payable.", "label": "Income Tax Receivable Agreement Payable [Member]", "terseLabel": "Income tax receivable agreement payable" } } }, "localname": "IncomeTaxReceivableAgreementPayableMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails", "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "ara_IncomeTaxReceivableChangesInFairValueGainLoss": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Income Tax Receivable, Changes In Fair Value, Gain (Loss)", "label": "Income Tax Receivable, Changes In Fair Value, Gain (Loss)", "negatedLabel": "Change in fair value of income tax receivable agreement", "terseLabel": "Change in fair value of income tax receivable agreement" } } }, "localname": "IncomeTaxReceivableChangesInFairValueGainLoss", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "ara_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Right-Of-Use Assets And Operating Lease Liabilities", "label": "Increase (Decrease) In Right-Of-Use Assets And Operating Lease Liabilities", "terseLabel": "Right-of-use assets and operating lease liabilities" } } }, "localname": "IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ara_KineticMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Kinetic [Member]", "label": "Kinetic [Member]", "terseLabel": "Kinetic" } } }, "localname": "KineticMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "ara_LeasesWeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leases, Weighted Average Discount Rate [Abstract]", "label": "Leases, Weighted Average Discount Rate [Abstract]", "terseLabel": "Weighted Average Discount Rate" } } }, "localname": "LeasesWeightedAverageDiscountRateAbstract", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "stringItemType" }, "ara_LegalFeesAndOther": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Legal Fees And Other", "label": "Legal Fees And Other", "terseLabel": "Certain legal and other matters (Note 15)" } } }, "localname": "LegalFeesAndOther", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "ara_LesseeFinanceLeaseLeaseNotYetCommencedLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Finance Lease, Lease Not Yet Commenced, Liability", "label": "Lessee, Finance Lease, Lease Not Yet Commenced, Liability", "terseLabel": "Finance lease not yet commenced, liability" } } }, "localname": "LesseeFinanceLeaseLeaseNotYetCommencedLiability", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ara_LesseeLeaseRenewalTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Lease, Renewal Term", "label": "Lessee, Lease, Renewal Term", "terseLabel": "Lease agreements renewal option period" } } }, "localname": "LesseeLeaseRenewalTerm", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESNarrativeDetails" ], "xbrltype": "durationItemType" }, "ara_LesseeLeaseTermOfContract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Lease, Term Of Contract", "label": "Lessee, Lease, Term Of Contract", "terseLabel": "Lease agreements cover periods" } } }, "localname": "LesseeLeaseTermOfContract", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESNarrativeDetails" ], "xbrltype": "durationItemType" }, "ara_LesseeOperatingLeaseLeaseNotYetCommencedLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability", "terseLabel": "Operating lease not yet commenced, liability" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLiability", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due", "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFive": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 7.0, "parentTag": "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, Payments Net Of Sublease Income, Due After Year Five", "label": "Lessee, Operating Lease, Liability, Payments Net Of Sublease Income, Due After Year Five", "totalLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFive", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details" ], "xbrltype": "monetaryItemType" }, "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 1.0, "parentTag": "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, Payments Net Of Sublease Income, Due After Year Four", "label": "Lessee, Operating Lease, Liability, Payments Net Of Sublease Income, Due After Year Four", "totalLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFive": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 8.0, "parentTag": "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Five", "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Five", "totalLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFive", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details" ], "xbrltype": "monetaryItemType" }, "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 6.0, "parentTag": "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Four", "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Four", "terseLabel": "2023", "totalLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 5.0, "parentTag": "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, Payments Net Of Sublease Income, Due Year One", "label": "Lessee, Operating Lease, Liability, Payments Net Of Sublease Income, Due Year One", "terseLabel": "2020", "totalLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 4.0, "parentTag": "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Three", "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three", "terseLabel": "2022", "totalLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 3.0, "parentTag": "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Two", "label": "Lessee, Operating Lease, Liability, Payments Net Of Sublease Income, Due Year Two", "terseLabel": "2021", "totalLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 2.0, "parentTag": "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Operating Lease Liability Payments Net Of Sublease Income Remainder Of Fiscal Year", "label": "Lessee, Operating Lease, Liability, Payments Net Of Sublease Income, Remainder Of Fiscal Year", "totalLabel": "2020 (excluding the six months ended June\u00a030, 2020)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "ara_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]", "label": "Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]", "terseLabel": "Net Operating Lease" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "stringItemType" }, "ara_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee\u200b, Operating \u200bLease\u200b, Liability, \u200bTo Be Paid, \u200bDue \u200bAfter\u200b Year\u200b Four", "label": "Lessee\u200b, Operating \u200bLease\u200b, Liability, \u200bTo Be Paid, \u200bDue \u200bAfter\u200b Year\u200b Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "ara_LessorOperatingLeasePaymentToBeReceivedAfterYearFour": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 2.0, "parentTag": "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Lessor, Operating Lease, Payment To Be Received, After Year Four", "label": "Lessor, Operating Lease, Payment To Be Received, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LessorOperatingLeasePaymentToBeReceivedAfterYearFour", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "ara_LineOfCreditFacilityAccordionFeatureIncreaseLimit": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Line Of Credit Facility, Accordion Feature, Increase Limit", "label": "Line Of Credit Facility, Accordion Feature, Increase Limit", "terseLabel": "Uncommitted incremental accordion facility, amount" } } }, "localname": "LineOfCreditFacilityAccordionFeatureIncreaseLimit", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ara_LineOfCreditFacilityAccordionFeatureIncreaseLimitPercentageOfConsolidatedEBITDA": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line Of Credit Facility, Accordion Feature, Increase Limit, Percentage Of Consolidated EBITDA", "label": "Line Of Credit Facility, Accordion Feature, Increase Limit, Percentage Of Consolidated EBITDA", "terseLabel": "Uncommitted incremental accordion facility, percentage of consolidated EBITDA" } } }, "localname": "LineOfCreditFacilityAccordionFeatureIncreaseLimitPercentageOfConsolidatedEBITDA", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "ara_LitigationSettlementAgreementTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Litigation Settlement, Agreement Term", "label": "Litigation Settlement, Agreement Term", "terseLabel": "Agreement term" } } }, "localname": "LitigationSettlementAgreementTerm", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "durationItemType" }, "ara_LitigationSettlementNumberOfPaymentInstallments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Litigation Settlement, Number Of Payment Installments", "label": "Litigation Settlement, Number Of Payment Installments", "terseLabel": "Number of installments" } } }, "localname": "LitigationSettlementNumberOfPaymentInstallments", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "integerItemType" }, "ara_LongTermDebtMaturityAfterYearFour": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/DEBTScheduledmaturitiesoflongtermdebtDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-Term Debt, Maturity, After Year Four", "label": "Long-Term Debt, Maturity, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturityAfterYearFour", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTScheduledmaturitiesoflongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "ara_LongtermDebtGrossAndLeaseObligationGross": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-term Debt, Gross And Lease Obligation, Gross", "label": "Long-term Debt, Gross And Lease Obligation, Gross", "totalLabel": "Long-term debt, gross" } } }, "localname": "LongtermDebtGrossAndLeaseObligationGross", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "ara_LukeJohnsonVJosephACarlucciEtAlMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Luke Johnson v. Joseph A. Carlucci, et al.", "label": "Luke Johnson v. Joseph A. Carlucci, et al. [Member]", "terseLabel": "Luke Johnson v. Joseph A. Carlucci, et al." } } }, "localname": "LukeJohnsonVJosephACarlucciEtAlMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "domainItemType" }, "ara_MedicaidAndManagedMedicaidRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicaid And Managed Medicaid Revenue [Member]", "label": "Medicaid And Managed Medicaid Revenue [Member]", "terseLabel": "Medicaid and Managed Medicaid" } } }, "localname": "MedicaidAndManagedMedicaidRevenueMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "ara_MedicareAcceleratedAndAdvancePaymentProgramPaymentCommencementPeriodPostPaymentIssuance": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare Accelerated And Advance Payment Program, Payment Commencement, Period Post Payment Issuance", "label": "Medicare Accelerated And Advance Payment Program, Payment Commencement, Period Post Payment Issuance", "terseLabel": "Medicare accelerated and advance payment program, payment commencement, period post payment issuance" } } }, "localname": "MedicareAcceleratedAndAdvancePaymentProgramPaymentCommencementPeriodPostPaymentIssuance", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "durationItemType" }, "ara_MedicareAcceleratedAndAdvancePaymentProgramPaymentRequestPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare Accelerated And Advance Payment Program, Payment Request, Percentage", "label": "Medicare Accelerated And Advance Payment Program, Payment Request, Percentage", "terseLabel": "Medicare accelerated and advance payment program, payment request" } } }, "localname": "MedicareAcceleratedAndAdvancePaymentProgramPaymentRequestPercentage", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "ara_MedicareAcceleratedAndAdvancePaymentProgramRequestedDuration": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare Accelerated And Advance Payment Program, Requested Duration", "label": "Medicare Accelerated And Advance Payment Program, Requested Duration", "terseLabel": "Medicare accelerated and advance payment program, payment request period" } } }, "localname": "MedicareAcceleratedAndAdvancePaymentProgramRequestedDuration", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "durationItemType" }, "ara_MedicareAndMedicareAdvantageRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare And Medicare Advantage Revenue [Member]", "label": "Medicare And Medicare Advantage Revenue [Member]", "terseLabel": "Medicare and Medicare Advantage" } } }, "localname": "MedicareAndMedicareAdvantageRevenueMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "ara_NetIncomeLossAttributableToParentNetOfTransfersToNoncontrollingInterest": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/CHANGESINOWNERSHIPINTERESTINCONSOLIDATEDSUBSIDIARIESDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to parent net of transfers to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Parent Net of Transfers to Noncontrolling Interest", "totalLabel": "Net loss attributable to American Renal Holdings Associates, Inc., net of transfers to/from noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToParentNetOfTransfersToNoncontrollingInterest", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CHANGESINOWNERSHIPINTERESTINCONSOLIDATEDSUBSIDIARIESDetails" ], "xbrltype": "monetaryItemType" }, "ara_NoncashChangeInLiabilitiesAssumed": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Noncash Change In Liabilities Assumed", "label": "Noncash Change In Liabilities Assumed", "terseLabel": "Change in liability accrued for dividend equivalent payments" } } }, "localname": "NoncashChangeInLiabilitiesAssumed", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ara_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Amount", "label": "Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Amount", "terseLabel": "Non-cash equity contributions" } } }, "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationAmount", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ara_NoncashOrPartNoncashDivestitureNoncashFinancialOrEquityInstrumentConsiderationAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Noncash Or Part Noncash Divestiture, Noncash Financial Or Equity Instrument Consideration, Amount", "label": "Noncash Or Part Noncash Divestiture, Noncash Financial Or Equity Instrument Consideration, Amount", "terseLabel": "Non-cash equity impacts of the sale or closure of clinics" } } }, "localname": "NoncashOrPartNoncashDivestitureNoncashFinancialOrEquityInstrumentConsiderationAmount", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ara_NoncontrollingInterestDecreasefromPurchaseofInterests": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/CHANGESINOWNERSHIPINTERESTINCONSOLIDATEDSUBSIDIARIESDetails": { "order": 1.0, "parentTag": "ara_NoncontrollingInterestNetTransfers", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Noncontrolling Interest, Decrease from Purchase of Interests", "label": "Noncontrolling Interest, Decrease from Purchase of Interests", "negatedLabel": "Purchases of equity of noncontrolling interests", "negatedTerseLabel": "Decrease in paid-in capital for the purchase of noncontrolling interest and adjustments to ownership interest" } } }, "localname": "NoncontrollingInterestDecreasefromPurchaseofInterests", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CHANGESINOWNERSHIPINTERESTINCONSOLIDATEDSUBSIDIARIESDetails", "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "ara_NoncontrollingInterestDecreasefromRedemptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Noncontrolling Interest, Decrease from Redemptions", "label": "Noncontrolling Interest, Decrease from Redemptions", "negatedTerseLabel": "Redemptions of equity of noncontrolling interests" } } }, "localname": "NoncontrollingInterestDecreasefromRedemptions", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "ara_NoncontrollingInterestIncreaseDecreaseFromSaleOfParentEquityInterest": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/CHANGESINOWNERSHIPINTERESTINCONSOLIDATEDSUBSIDIARIESDetails": { "order": 2.0, "parentTag": "ara_NoncontrollingInterestNetTransfers", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Noncontrolling Interest, Increase (Decrease) From Sale Of Parent Equity Interest", "label": "Noncontrolling Interest, Increase (Decrease) From Sale Of Parent Equity Interest", "verboseLabel": "Increase in paid-in capital for the sales of noncontrolling interest" } } }, "localname": "NoncontrollingInterestIncreaseDecreaseFromSaleOfParentEquityInterest", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CHANGESINOWNERSHIPINTERESTINCONSOLIDATEDSUBSIDIARIESDetails" ], "xbrltype": "monetaryItemType" }, "ara_NoncontrollingInterestIncreaseFromContributions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Noncontrolling interest increase from contributions.", "label": "Noncontrolling Interest Increase From Contributions", "terseLabel": "Contributions from noncontrolling interests" } } }, "localname": "NoncontrollingInterestIncreaseFromContributions", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "ara_NoncontrollingInterestNetTransfers": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/CHANGESINOWNERSHIPINTERESTINCONSOLIDATEDSUBSIDIARIESDetails": { "order": 2.0, "parentTag": "ara_NetIncomeLossAttributableToParentNetOfTransfersToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net transfers to noncontrolling interest .", "label": "Noncontrolling Interest, Net Transfers", "negatedTotalLabel": "Net transfers to/from noncontrolling interests" } } }, "localname": "NoncontrollingInterestNetTransfers", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CHANGESINOWNERSHIPINTERESTINCONSOLIDATEDSUBSIDIARIESDetails" ], "xbrltype": "monetaryItemType" }, "ara_NoncontrollingInterestNoPutProvisionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents noncontrolling interests not subject to put provisions", "label": "Noncontrolling Interest No Put Provision [Member]", "terseLabel": "Noncontrolling Interests Not Subject to Put Provisions" } } }, "localname": "NoncontrollingInterestNoPutProvisionMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "domainItemType" }, "ara_NoncontrollingInterestPutProvisionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents noncontrolling interests subject to put provisions", "label": "Noncontrolling Interest Put Provision [Member]", "terseLabel": "Noncontrolling Interests Subject to Put Provisions" } } }, "localname": "NoncontrollingInterestPutProvisionMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity", "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "domainItemType" }, "ara_NotesPayableCurrentAndNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the amount for intercompany term loans.", "label": "Notes Payable Current And NonCurrent", "terseLabel": "Assigned clinic loans" } } }, "localname": "NotesPayableCurrentAndNoncurrent", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "ara_NumberOfDialysisClinicsOwnedAndOperated": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of dialysis clinics owned and operated by the company.", "label": "Number of Dialysis Clinics Owned and Operated", "terseLabel": "Number of dialysis clinics owned and operated" } } }, "localname": "NumberOfDialysisClinicsOwnedAndOperated", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "integerItemType" }, "ara_NumberOfPatients": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of patients treated.", "label": "Number of Patients", "terseLabel": "Number of patients company treats" } } }, "localname": "NumberOfPatients", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "integerItemType" }, "ara_NumberofPerformanceObligations": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Performance Obligations", "label": "Number of Performance Obligations", "terseLabel": "Number of performance obligations" } } }, "localname": "NumberofPerformanceObligations", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "integerItemType" }, "ara_OmnibusIncentivePlanTwentySixteenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Relates to the 2016 Omnibus Incentive Plan.", "label": "Omnibus Incentive Plan Twenty Sixteen [Member]", "terseLabel": "2016 Omnibus Incentive Plan" } } }, "localname": "OmnibusIncentivePlanTwentySixteenMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "domainItemType" }, "ara_OperatingExpenseOffsetByGrantFundsCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating Expense Offset By Grant Funds, CARES Act", "label": "Operating Expense Offset By Grant Funds, CARES Act", "terseLabel": "Operating expenses offset by grant funds, CARES Act" } } }, "localname": "OperatingExpenseOffsetByGrantFundsCARESAct", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "ara_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating Lease Assets And Liabilities, Lessee [Abstract]", "label": "Operating Lease Assets And Liabilities, Lessee [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseAssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "stringItemType" }, "ara_OtherLineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Line Of Credit [Member]", "label": "Other Line Of Credit [Member]", "terseLabel": "Other Lines of Credit" } } }, "localname": "OtherLineOfCreditMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "domainItemType" }, "ara_OtherRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Revenue [Member]", "label": "Other Revenue [Member]", "terseLabel": "Other" } } }, "localname": "OtherRevenueMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "ara_OtherTermLoansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Term Loans [Member]", "label": "Other Term Loans [Member]", "terseLabel": "Other Term Loans" } } }, "localname": "OtherTermLoansMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "domainItemType" }, "ara_OwnershipInterestInJointVenture": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Ownership Interest In Joint Venture", "label": "Ownership Interest In Joint Venture", "terseLabel": "Ownership interest in joint venture" } } }, "localname": "OwnershipInterestInJointVenture", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "ara_OwnershipPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ownership Percentage", "label": "Ownership Percentage", "terseLabel": "Ownership percentage" } } }, "localname": "OwnershipPercentage", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "percentItemType" }, "ara_PatientCareCosts": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Patient care costs are costs directly associated with operating and supporting dialysis centers, medical clinics and ancillary operations and consist principally of labor, pharmaceuticals, medical supplies and facility operating costs.", "label": "Patient Care Costs", "terseLabel": "Patient care costs" } } }, "localname": "PatientCareCosts", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "ara_PaymentsForUtilizationOfGrantFundsCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments For Utilization Of Grant Funds, CARES Act", "label": "Payments For Utilization Of Grant Funds, CARES Act", "terseLabel": "Amounts utilized under the grant funds, CARES Act" } } }, "localname": "PaymentsForUtilizationOfGrantFundsCARESAct", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "ara_PaymentsOnTaxReceivableAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments On Tax Receivable Agreement", "label": "Payments On Tax Receivable Agreement", "terseLabel": "Payments made for the income tax receivable agreement" } } }, "localname": "PaymentsOnTaxReceivableAgreement", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "ara_PaymentsRelatedToRepurchasesOfVestedRestrictedStockAwardsWithheldOnNetShareSettlement": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments Related To Repurchases Of Vested Restricted Stock Awards Withheld On Net Share Settlement", "label": "Payments Related To Repurchases Of Vested Restricted Stock Awards Withheld On Net Share Settlement", "negatedLabel": "Repurchase of vested restricted stock awards withheld on net share settlement" } } }, "localname": "PaymentsRelatedToRepurchasesOfVestedRestrictedStockAwardsWithheldOnNetShareSettlement", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ara_PercentageOfReceivableUnderGovernmentsBundledPaymentSystem": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents percentage of payment received under government\u2019s bundled payment system.", "label": "Percentage Of Receivable under Government\u2019s Bundled Payment System", "terseLabel": "Percentage of receivable under government\u2019s bundled payment system" } } }, "localname": "PercentageOfReceivableUnderGovernmentsBundledPaymentSystem", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "percentItemType" }, "ara_PercentageTaxSavingsPayableToStockholders": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage of cash savings in U.S. federal, state and local income tax realized as a result of any deductions (including net operating losses resulting from such deductions) attributable to the exercise of (or any payment, including any dividend equivalent right or payment, in respect of) any compensatory stock option issued payable to our pre-IPO stockholders on a pro rata basis.", "label": "Percentage Tax Savings Payable To Stockholders", "terseLabel": "Percentage tax savings payable to pre-IPO stockholders" } } }, "localname": "PercentageTaxSavingsPayableToStockholders", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "percentItemType" }, "ara_PeriodOfWeightedAverageMaturity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average maturity (weighted by amount of the agreement), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Period Of Weighted Average Maturity", "terseLabel": "Period of weighted average maturity, clinic loans" } } }, "localname": "PeriodOfWeightedAverageMaturity", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "durationItemType" }, "ara_ProceedsFromGrantFundCARESAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From Grant Fund, CARES Act", "label": "Proceeds From Grant Fund, CARES Act", "terseLabel": "Proceeds from grant fund, CARES Act" } } }, "localname": "ProceedsFromGrantFundCARESAct", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "ara_ReceivableFromNoncontrollingInterest": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Receivable due from noncontrolling interest.", "label": "Receivable From Noncontrolling Interest", "negatedTerseLabel": "Receivable from noncontrolling interests" } } }, "localname": "ReceivableFromNoncontrollingInterest", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ara_RedeemableNoncontrollingInterestEquityAcceleratedPortionRedemptionValue": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Redeemable Noncontrolling Interest, Equity, Accelerated Portion, Redemption Value", "label": "Redeemable Noncontrolling Interest, Equity, Accelerated Portion, Redemption Value", "totalLabel": "Redemption value" } } }, "localname": "RedeemableNoncontrollingInterestEquityAcceleratedPortionRedemptionValue", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "monetaryItemType" }, "ara_RedeemableNoncontrollingInterestEquityFairValueAcceleratedPortion": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails": { "order": 1.0, "parentTag": "ara_RedeemableNoncontrollingInterestEquityAcceleratedPortionRedemptionValue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Redeemable Noncontrolling Interest, Equity, Fair Value, Accelerated Portion", "label": "Redeemable Noncontrolling Interest, Equity, Fair Value, Accelerated Portion", "terseLabel": "Estimated fair values for accounting purposes" } } }, "localname": "RedeemableNoncontrollingInterestEquityFairValueAcceleratedPortion", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "monetaryItemType" }, "ara_RedeemableNoncontrollingInterestEquityFairValueAcceleratedPortionFairValueAdjustment": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails": { "order": 2.0, "parentTag": "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Redeemable Noncontrolling Interest, Equity, Fair Value, Accelerated Portion, Fair Value Adjustment", "label": "Redeemable Noncontrolling Interest, Equity, Fair Value, Accelerated Portion, Fair Value Adjustment", "terseLabel": "Difference between the redemption value and estimated fair value for accounting purposes of the related noncontrolling interests" } } }, "localname": "RedeemableNoncontrollingInterestEquityFairValueAcceleratedPortionFairValueAdjustment", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "monetaryItemType" }, "ara_RedeemableNoncontrollingInterestEquityFairValueMeasurementInput": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Redeemable Noncontrolling Interest, Equity, Fair Value, Measurement Input", "label": "Redeemable Noncontrolling Interest, Equity, Fair Value, Measurement Input", "terseLabel": "Weighted average cost of capital" } } }, "localname": "RedeemableNoncontrollingInterestEquityFairValueMeasurementInput", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "decimalItemType" }, "ara_RedeemableNoncontrollingInterestEquityPutProvisionLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Redeemable Noncontrolling Interest, Equity, Put Provision Liability, Current", "label": "Redeemable Noncontrolling Interest, Equity, Put Provision Liability, Current", "terseLabel": "IPO put liability" } } }, "localname": "RedeemableNoncontrollingInterestEquityPutProvisionLiabilityCurrent", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "ara_RelatedPartyTransactionLoanGuarantee": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Related Party Transaction, Loan Guarantee", "label": "Related Party Transaction, Loan Guarantee", "terseLabel": "Loan guarantee outstanding" } } }, "localname": "RelatedPartyTransactionLoanGuarantee", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "ara_RevenueFromContractWithCustomerExcludingAssessedTaxDueToTemporarySuspensionOfAutomatic2ReductionOfMedicareProgramPaymentsCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue From Contract With Customer, Excluding Assessed Tax, Due To Temporary Suspension Of Automatic 2% Reduction Of Medicare Program Payments, CARES Act", "label": "Revenue From Contract With Customer, Excluding Assessed Tax, Due To Temporary Suspension Of Automatic 2% Reduction Of Medicare Program Payments, CARES Act", "terseLabel": "Revenue received from temporary suspension of automatic 2% reduction of medicare program payments, CARES Act" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxDueToTemporarySuspensionOfAutomatic2ReductionOfMedicareProgramPaymentsCARESAct", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "ara_RevenueFromContractWithCustomerPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue From Contract With Customer, Percent", "label": "Revenue From Contract With Customer, Percent", "terseLabel": "Patient care service revenue" } } }, "localname": "RevenueFromContractWithCustomerPercent", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "percentItemType" }, "ara_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract]", "label": "Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract]", "terseLabel": "Right-of-use assets obtained in exchange for new or modified lease obligations:" } } }, "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalcashflowrelatedtoleasesDetails" ], "xbrltype": "stringItemType" }, "ara_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Employee Related Liabilities [Table Text Block]", "label": "Schedule Of Employee Related Liabilities [Table Text Block]", "terseLabel": "Summary of accrued compensation and benefits" } } }, "localname": "ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" ], "xbrltype": "textBlockItemType" }, "ara_ShareBasedPaymentArrangementPlanModificationIncrementalCostCredit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost (Credit)", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost (Credit)", "terseLabel": "Additional stock compensation expense (credit) related to plan modification" } } }, "localname": "ShareBasedPaymentArrangementPlanModificationIncrementalCostCredit", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ara_SoftwareServicesAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Software Services Agreement [Member]", "label": "Software Services Agreement [Member]", "terseLabel": "Software services agreement" } } }, "localname": "SoftwareServicesAgreementMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "ara_TaxReceivableAgreementLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Tax Receivable Agreement Liability, Current", "label": "Tax Receivable Agreement Liability, Current", "terseLabel": "Accrued settlement" } } }, "localname": "TaxReceivableAgreementLiabilityCurrent", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "ara_TemporaryEquityAccretiontoRedemptionValueContractual": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails": { "order": 2.0, "parentTag": "us-gaap_MinorityInterestChangeInRedemptionValue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Temporary Equity, Accretion to Redemption Value, Contractual", "label": "Temporary Equity, Accretion to Redemption Value, Contractual", "terseLabel": "Change in the difference between the redemption value and estimated fair value for accounting purposes of the related noncontrolling interests" } } }, "localname": "TemporaryEquityAccretiontoRedemptionValueContractual", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "monetaryItemType" }, "ara_TemporaryEquityTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity [Text Block]", "verboseLabel": "NONCONTROLLING INTERESTS SUBJECT TO PUT PROVISIONS" } } }, "localname": "TemporaryEquityTextBlock", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONS" ], "xbrltype": "textBlockItemType" }, "ara_TermBLoansDueSeptember2019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information about Term B Loans issued March 22, 2013 with a balloon payment due September 2019.", "label": "Term B Loans Due September2019 [Member]", "terseLabel": "Term B loans" } } }, "localname": "TermBLoansDueSeptember2019Member", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "ara_ThirdPartiesToClinicLoanAgreementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Third Parties To Clinic Loan Agreements [Member]", "label": "Third Parties To Clinic Loan Agreements [Member]", "terseLabel": "Third Parties to Clinic Loan Agreements" } } }, "localname": "ThirdPartiesToClinicLoanAgreementsMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "ara_ThirdPartyClinicLoanAgreementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Third-Party Clinic Loan Agreements", "label": "Third-Party Clinic Loan Agreements [Member]", "terseLabel": "Third-Party Clinic Loan Agreements" } } }, "localname": "ThirdPartyClinicLoanAgreementsMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "ara_TransitionServicesAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transition Services Agreement [Member]", "label": "Transition Services Agreement [Member]", "terseLabel": "Transition Services Agreement" } } }, "localname": "TransitionServicesAgreementMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "ara_UnvestedOptionStockholdersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per-IPO stockholders with options which are not vested.", "label": "Unvested Option Stockholders [Member]", "terseLabel": "Unvested option stockholders" } } }, "localname": "UnvestedOptionStockholdersMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "ara_VestedOptionStockholdersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per-IPO stockholders with options which are fully vested.", "label": "Vested Option Stockholders [Member]", "terseLabel": "Vested option stockholders" } } }, "localname": "VestedOptionStockholdersMember", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "ara_WeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted Average Remaining Lease Term [Abstract]", "label": "Weighted Average Remaining Lease Term [Abstract]", "terseLabel": "Weighted Average Remaining Lease Term" } } }, "localname": "WeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://www.americanrenal.com/20200630", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r541" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r542" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r543" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r543" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r545" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r543" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r544" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r543" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r543" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r543" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r543" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r539" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r540" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.americanrenal.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r362", "r363", "r370", "r371", "r538" ], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/VARIABLEINTERESTENTITIESDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r362", "r363", "r370", "r371" ], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/VARIABLEINTERESTENTITIESDetails" ], "xbrltype": "domainItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "label": "Executive Officer [Member]", "terseLabel": "Executive", "verboseLabel": "Certain executives" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r287", "r289", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r523", "r525" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/LEASESNarrativeDetails", "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails", "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r287", "r289", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r523", "r525" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/LEASESNarrativeDetails", "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails", "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r186", "r264", "r267", "r471", "r522", "r524" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r186", "r264", "r267", "r471", "r522", "r524" ], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r276", "r287", "r289", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r523", "r525" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/LEASESNarrativeDetails", "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails", "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r276", "r287", "r289", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r523", "r525" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/LEASESNarrativeDetails", "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails", "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r189", "r454" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r18", "r35", "r190", "r191" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails", "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued expenses and other current liabilities:" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r22", "r23", "r51" ], "calculation": { "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 1.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "terseLabel": "Accrued compensation" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedVacationCurrent": { "auth_ref": [ "r22", "r51", "r275" ], "calculation": { "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 2.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Vacation, Current", "terseLabel": "Accrued vacation pay" } } }, "localname": "AccruedVacationCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r38", "r68", "r69", "r70", "r509", "r533", "r537" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss, net of tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r67", "r70", "r72", "r124", "r125", "r126", "r368", "r528", "r529" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalFairValueElementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Additional Fair Value Elements [Abstract]", "terseLabel": "Temporary Equity" } } }, "localname": "AdditionalFairValueElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r36", "r327" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r124", "r125", "r126", "r324", "r325", "r326" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Vested restricted stock awards withheld on net share settlement" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r290", "r293", "r330", "r331" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r293", "r316", "r329" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation before tax" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONScheduleofexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r105", "r423" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of discounts, fees and deferred financing costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Outstanding options and restricted stock excluded as impact would be anti-dilutive (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r105", "r209" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Asset impairment charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r114", "r169", "r178", "r184", "r195", "r362", "r370", "r411", "r488", "r507" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets", "verboseLabel": "Total assets of VIEs" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets", "http://www.americanrenal.com/role/VARIABLEINTERESTENTITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r20", "r21", "r63", "r114", "r195", "r362", "r370", "r411" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r9", "r11", "r14", "r216" ], "calculation": { "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "terseLabel": "Current assets held for sale", "totalLabel": "Total assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALENarrativeDetails", "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r193", "r202" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Current assets held for sale" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r294", "r318" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONSTOCKBASEDCOMPENSATIONAssumptionsusedforoptionsgrantedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails", "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r386", "r389" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails", "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "BASIS OF PRESENTATION, ORGANIZATION AND RECENT EVENTS" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r109", "r110", "r111" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Non-cash purchases of property and equipment" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r16", "r44", "r107" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r100", "r107", "r112" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and restricted cash at end of period", "periodStartLabel": "Cash and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r100", "r412" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase in cash and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r384" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash flow hedge" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental Disclosure of Non-Cash Financing Activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r56", "r223", "r495", "r513" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 14 and Note 15)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r220", "r221", "r222", "r230" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r124", "r125" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in USD per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r33", "r246" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r33" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.01 par value; 300,000,000 shares authorized; 34,488,565 and 32,976,416\u00a0issued and outstanding at June\u00a030, 2020 and December\u00a031, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r74", "r76", "r77", "r82", "r499", "r519" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income (loss) attributable to American Renal Associates Holdings, Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r74", "r76", "r81", "r360", "r361", "r379", "r498", "r518" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "negatedTerseLabel": "Less: Comprehensive income attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r74", "r76", "r80", "r359", "r379", "r497", "r517" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock": { "auth_ref": [ "r369", "r380" ], "lang": { "en-US": { "role": { "documentation": "The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.", "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]", "terseLabel": "Schedule of effect of changes in company's ownership interest on company's equity" } } }, "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CHANGESINOWNERSHIPINTERESTINCONSOLIDATEDSUBSIDIARIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r113", "r364" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r253", "r254", "r265" ], "calculation": { "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue - advanced payments from CMS", "verboseLabel": "Deferred revenue, advanced payments from Centers for Medicare and Medicaid Services" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r85" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRefundLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.", "label": "Customer Refund Liability, Current", "terseLabel": "Refunds due to payors" } } }, "localname": "CustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBT" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r29", "r30", "r31", "r489", "r490", "r506" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Interest rate margin" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r31", "r235", "r490", "r506" ], "calculation": { "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails": { "order": 2.0, "parentTag": "ara_LongtermDebtGrossAndLeaseObligationGross", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r422", "r424" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r409" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value of debt" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r53", "r422" ], "lang": { "en-US": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "verboseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r53" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r54" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r54" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Principal payments" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r504" ], "lang": { "en-US": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r504" ], "lang": { "en-US": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r504" ], "lang": { "en-US": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Debt Instrument, Redemption, Period One" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r504" ], "lang": { "en-US": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "Debt Instrument, Redemption, Period Two" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r504" ], "lang": { "en-US": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Debt redemption price, percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r54", "r118", "r247", "r248", "r249", "r250", "r421", "r422", "r424", "r505" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r236", "r423" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedLabel": "Less: discounts and fees, net of accumulated amortization" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average interest rate of debt outstanding.", "label": "Debt, Weighted Average Interest Rate", "terseLabel": "Weighted average interest rate" } } }, "localname": "DebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r105", "r115", "r342", "r349", "r350", "r351" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r333", "r334" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r65", "r66", "r409" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Interest rate derivative agreements asset" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r387", "r388", "r390", "r393" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r385", "r387", "r390" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r65", "r66", "r409" ], "calculation": { "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails": { "order": 2.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Interest rate swap agreement" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r382", "r383" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Interest rate swap and cap agreements notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "auth_ref": [ "r382", "r383" ], "lang": { "en-US": { "role": { "documentation": "The number of derivative instruments of a particular group held by the entity.", "label": "Derivative, Number of Instruments Held", "terseLabel": "Number of interest rate swap agreements" } } }, "localname": "DerivativeNumberOfInstrumentsHeld", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r385" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as hedge" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r264", "r267", "r268", "r269", "r270", "r271", "r272", "r273" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Sources of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/REVENUETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r332" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]", "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALENarrativeDetails", "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails", "http://www.americanrenal.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALENarrativeDetails", "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails", "http://www.americanrenal.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r210", "r217" ], "lang": { "en-US": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r11", "r208", "r217" ], "lang": { "en-US": { "role": { "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALENarrativeDetails", "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": { "auth_ref": [ "r0", "r1", "r9", "r216" ], "calculation": { "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails": { "order": 5.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Goodwill", "terseLabel": "Goodwill" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails", "http://www.americanrenal.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "auth_ref": [ "r0", "r1", "r9", "r216" ], "calculation": { "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Inventory", "terseLabel": "Inventories" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "auth_ref": [ "r0", "r1", "r9", "r211", "r216" ], "calculation": { "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "auth_ref": [ "r0", "r1", "r9", "r216" ], "calculation": { "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "terseLabel": "Property and equipment, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "auth_ref": [ "r8", "r14" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Revenue" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r15", "r219" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "ASSETS HELD FOR SALE" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALE" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r286", "r288" ], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALENarrativeDetails", "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails", "http://www.americanrenal.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r251", "r503" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Cash", "terseLabel": "Cash dividend" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r121", "r452", "r493", "r514" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due from Related Parties", "terseLabel": "Future rental receipts due from related party" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESNarrativeDetails", "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r19", "r27", "r34", "r116", "r452" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due from Related Parties, Current", "terseLabel": "Amount outstanding, current" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedPartiesNoncurrent": { "auth_ref": [ "r45", "r121", "r452" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).", "label": "Due from Related Parties, Noncurrent", "terseLabel": "Amount outstanding, noncurrent" } } }, "localname": "DueFromRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "Earnings (loss) per share (Note 12):" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r83", "r133", "r134", "r135", "r136", "r137", "r141", "r144", "r147", "r148", "r149", "r153", "r154", "r500", "r520" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in USD per share)", "verboseLabel": "Earnings (loss) per share, basic (in USD per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations", "http://www.americanrenal.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r83", "r133", "r134", "r135", "r136", "r137", "r144", "r147", "r148", "r149", "r153", "r154", "r500", "r520" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in USD per share)", "verboseLabel": "Earnings (loss) per share, diluted (in USD per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations", "http://www.americanrenal.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r150", "r151", "r152", "r155" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "EARNINGS (LOSS) PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/EARNINGSLOSSPERSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/INCOMETAXESDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and benefits", "totalLabel": "Accrued compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Employee-related Liabilities, Current [Abstract]", "terseLabel": "Accrued compensation and benefits:" } } }, "localname": "EmployeeRelatedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONScheduleofexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r317" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation costs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation costs recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r314" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Share-based Payment Arrangement, Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r124", "r125", "r126", "r129", "r138", "r140", "r156", "r199", "r246", "r251", "r324", "r325", "r326", "r345", "r346", "r413", "r414", "r415", "r416", "r417", "r418", "r528", "r529", "r530" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity", "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Percentage ownership of subsidiary" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EurodollarMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.", "label": "Eurodollar [Member]", "terseLabel": "Eurodollar one-month rate" } } }, "localname": "EurodollarMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r397", "r398", "r399", "r407" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails", "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings [Abstract]", "terseLabel": "Total realized/unrealized losses:" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSFairvaluerollforwardfortaxreceivableagreementliabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r397", "r410" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Schedule of the fair value of financial instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r285", "r398", "r461", "r462", "r463" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r397", "r398", "r401", "r402", "r408" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r406" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r277", "r278", "r283", "r285", "r398", "r461" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r277", "r278", "r283", "r285", "r398", "r462" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "verboseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r285", "r398", "r463" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations": { "auth_ref": [ "r397", "r398" ], "calculation": { "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails": { "order": 1.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of obligations measured on a recurring basis.", "label": "Obligations, Fair Value Disclosure", "terseLabel": "Tax receivable agreement liability", "verboseLabel": "Fair value of tax receivable agreement liability" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisObligations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails", "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSFairvaluerollforwardfortaxreceivableagreementliabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r403", "r407" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair value rollforward for the tax receivable agreement liability, which is classified as a level 3 financial instrument" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r404" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Included in earnings and reported as Change in fair value of income tax receivable agreement" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSFairvaluerollforwardfortaxreceivableagreementliabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r403" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance at June 30, 2020", "periodStartLabel": "Balance at December 31, 2019" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSFairvaluerollforwardfortaxreceivableagreementliabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r285", "r461", "r462", "r463" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r406", "r408" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "auth_ref": [ "r405" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income for derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3) and still held.", "label": "Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)", "terseLabel": "Change in fair value of derivative agreements, net of tax" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "terseLabel": "Federal funds effective rate" } } }, "localname": "FederalFundsEffectiveSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r428", "r435", "r446" ], "calculation": { "http://www.americanrenal.com/role/LEASESLeasecostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESLeasecostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r431", "r440" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalcashflowrelatedtoleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r426", "r445" ], "calculation": { "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails": { "order": 1.0, "parentTag": "ara_LongtermDebtGrossAndLeaseObligationGross", "weight": 1.0 }, "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details_1": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Present value of lease liabilities", "totalLabel": "Total finance lease liabilities", "verboseLabel": "Finance Lease Obligations" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details", "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r426" ], "calculation": { "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Current portion of long-term debt" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r427" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]", "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r445" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Future minimum lease payments under noncancelable finance leases" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r426" ], "calculation": { "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term debt, less current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r427" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 7.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2021", "verboseLabel": "2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 8.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five", "verboseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2024", "verboseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2023", "verboseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2022", "verboseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2020 (excluding the six months ended June\u00a030, 2020)" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: amount representing interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r430", "r440" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalcashflowrelatedtoleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r425" ], "calculation": { "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "totalLabel": "Property and equipment, net" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "auth_ref": [ "r428", "r435" ], "calculation": { "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "negatedLabel": "Accumulated depreciation" } } }, "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r428", "r435", "r446" ], "calculation": { "http://www.americanrenal.com/role/LEASESLeasecostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESLeasecostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [ "r425" ], "calculation": { "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "terseLabel": "Property and equipment, at cost" } } }, "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r427" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]", "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r443", "r446" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r442", "r446" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]", "terseLabel": "Assets" } } }, "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "totalLabel": "Total Liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r207" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated amortization of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r105" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Loss (gain) on disposal of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r86" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONScheduleofexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r203", "r204", "r487" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r385", "r394" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r385" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r385" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember": { "auth_ref": [ "r451", "r452" ], "lang": { "en-US": { "role": { "documentation": "Family member whom a principal owner or a member of management might control or influence, or by whom they might be controlled or influenced, because of the family relationship.", "label": "Immediate Family Member of Management or Principal Owner [Member]", "terseLabel": "Spouse of executive" } } }, "localname": "ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r120", "r169", "r177", "r180", "r183", "r185" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r286", "r288" ], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALENarrativeDetails", "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails", "http://www.americanrenal.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALENarrativeDetails", "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r6", "r7", "r10", "r12", "r13", "r14", "r217", "r218" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALENarrativeDetails", "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONScheduleofexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONScheduleofexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r337", "r338", "r340", "r347", "r352", "r354", "r355", "r356" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r115", "r139", "r140", "r168", "r335", "r348", "r353", "r521" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r108" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r60", "r494", "r515" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Income tax receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r104" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r104" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r104" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r104" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r104" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities, net of acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r104" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r104" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r205", "r206" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net of accumulated amortization of $25,502 and $25,087, respectively" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r78", "r167", "r420", "r423", "r501" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r98", "r101", "r108" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCapMember": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount.", "label": "Interest Rate Cap [Member]", "terseLabel": "Interest rate cap agreements" } } }, "localname": "InterestRateCapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swap agreements" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r17", "r62" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r444", "r446" ], "calculation": { "http://www.americanrenal.com/role/LEASESLeasecostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESLeasecostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Finance lease cost:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESLeasecostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r444" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of lease expenses and supplemental cash flow information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "CERTAIN LEGAL AND OTHER MATTERS" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERS" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeFinanceLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r433" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's finance lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Finance Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Finance lease not yet commenced lease term" } } }, "localname": "LesseeFinanceLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r447" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r434" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r433" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Operating lease not yet commenced lease term" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r445" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Future minimum lease payments under noncancelable operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details": { "order": 1.0, "parentTag": "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFive", "weight": 1.0 }, "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 8.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2021", "verboseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details": { "order": 2.0, "parentTag": "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFive", "weight": 1.0 }, "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 7.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2024", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2023", "verboseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2022", "verboseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 1.0, "parentTag": "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2020 (excluding the six months ended June\u00a030, 2020)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r445" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: amount representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r447" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]", "terseLabel": "Less: Sublease Income" } } }, "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r448" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "totalLabel": "Total minimum lease payments" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r448" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details": { "order": 1.0, "parentTag": "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFive", "weight": -1.0 }, "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 7.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "verboseLabel": "2024" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r448" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 2.0, "parentTag": "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "terseLabel": "2024", "verboseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r448" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 5.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "terseLabel": "2021", "verboseLabel": "2020" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "auth_ref": [ "r448" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year", "terseLabel": "2020 (excluding the six months ended June\u00a030, 2020)" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "auth_ref": [ "r448" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details": { "order": 2.0, "parentTag": "ara_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFive", "weight": -1.0 }, "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 8.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r448" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 4.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "terseLabel": "2023", "verboseLabel": "2022" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r448" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details": { "order": 6.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "terseLabel": "2022", "verboseLabel": "2021" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r50", "r114", "r179", "r195", "r363", "r370", "r371", "r411" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Total liabilities of VIEs", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets", "http://www.americanrenal.com/role/VARIABLEINTERESTENTITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r41", "r114", "r195", "r411", "r492", "r512" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAssumed1": { "auth_ref": [ "r109", "r110", "r111" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.", "label": "Liabilities Assumed", "terseLabel": "Liability established for IPO Put liability (Note 5)" } } }, "localname": "LiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r52", "r114", "r195", "r363", "r370", "r371", "r411" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r9", "r11", "r14", "r216" ], "calculation": { "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "terseLabel": "Current liabilities held for sale", "totalLabel": "Current liabilities held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALENarrativeDetails", "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails", "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LienCategoryAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by category of lien, for example, but not limited to, senior or junior.", "label": "Lien Category [Axis]", "terseLabel": "Lien Category [Axis]" } } }, "localname": "LienCategoryAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LienCategoryDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Legal claim on the property of another party to secure the payment of a debt or the satisfaction of an obligation by category, for example, but not limited to, senior or junior.", "label": "Lien Category [Domain]", "terseLabel": "Lien Category [Domain]" } } }, "localname": "LienCategoryDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Legal form of business company offering limited liability to its owners (denoted by L.L.C. or LLC in the U.S.).", "label": "Limited Liability Company [Member]", "terseLabel": "American Renal Holdings Intermediate Company, LLC" } } }, "localname": "LimitedLiabilityCompanyMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r31", "r490", "r506" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Revolving credit facility borrowings outstanding" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r49" ], "lang": { "en-US": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Interest rate at period end" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Aggregate amount of borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Undrawn commitment fee" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "2017 Credit Agreement - Revolving Credit Facility", "verboseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r56", "r223" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Estimated litigation liability" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount awarded from other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Litigation settlement, amount awarded from other party" } } }, "localname": "LitigationSettlementAmountAwardedFromOtherParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Litigation settlement, amount awarded to other party" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LoansPayableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Borrowing supported by a written promise to pay an obligation.", "label": "Loans Payable [Member]", "terseLabel": "Assigned Clinic Loans due to Term Loan Holdings" } } }, "localname": "LoansPayableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR rate, adjusted for changes in Eurodollar reserves" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r31", "r237", "r490", "r508" ], "calculation": { "http://www.americanrenal.com/role/DEBTScheduledmaturitiesoflongtermdebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Carrying amount of long-term debt", "totalLabel": "Carrying amount of long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTScheduledmaturitiesoflongtermdebtDetails", "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r31" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term Debt and Lease Obligation", "terseLabel": "Long-term debt, less current portion" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets", "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-term Debt and Lease Obligation, Current", "negatedLabel": "Less: current maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets", "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r122", "r233" ], "calculation": { "http://www.americanrenal.com/role/DEBTScheduledmaturitiesoflongtermdebtDetails": { "order": 6.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTScheduledmaturitiesoflongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r122", "r233" ], "calculation": { "http://www.americanrenal.com/role/DEBTScheduledmaturitiesoflongtermdebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTScheduledmaturitiesoflongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r122", "r233" ], "calculation": { "http://www.americanrenal.com/role/DEBTScheduledmaturitiesoflongtermdebtDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTScheduledmaturitiesoflongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r122", "r233" ], "calculation": { "http://www.americanrenal.com/role/DEBTScheduledmaturitiesoflongtermdebtDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2022", "verboseLabel": "Repayment of debt during second quarter of 2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/DEBTScheduledmaturitiesoflongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r122" ], "calculation": { "http://www.americanrenal.com/role/DEBTScheduledmaturitiesoflongtermdebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2020 (remainder)", "verboseLabel": "Repayment of debt during 2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/DEBTScheduledmaturitiesoflongtermdebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r54" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r54", "r234" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r231", "r232" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r400" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Weighted Average Cost of Capital" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r400" ], "lang": { "en-US": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MediumTermNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instruments with maturities ranging from five to ten years.", "label": "Medium-term Notes [Member]", "terseLabel": "Term loans", "verboseLabel": "2017 Credit Agreement - Term B Loan Facility" } } }, "localname": "MediumTermNotesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r61", "r114", "r195", "r411", "r491", "r511" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests not subject to put provisions" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestChangeInRedemptionValue": { "auth_ref": [ "r242", "r243", "r244", "r252" ], "calculation": { "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.", "label": "Noncontrolling Interest, Change in Redemption Value", "terseLabel": "Change in fair value of noncontrolling interests", "totalLabel": "Total change in fair value of noncontrolling interests subject to put provisions stated at maximum redemption" } } }, "localname": "MinorityInterestChangeInRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity", "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedLabel": "Distributions to noncontrolling interests" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r100" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r100" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r100", "r103", "r106" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r14", "r73", "r75", "r79", "r106", "r114", "r128", "r133", "r134", "r135", "r136", "r139", "r140", "r145", "r169", "r177", "r180", "r183", "r185", "r195", "r411", "r496", "r516" ], "calculation": { "http://www.americanrenal.com/role/CHANGESINOWNERSHIPINTERESTINCONSOLIDATEDSUBSIDIARIESDetails": { "order": 1.0, "parentTag": "ara_NetIncomeLossAttributableToParentNetOfTransfersToNoncontrollingInterest", "weight": 1.0 }, "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://www.americanrenal.com/role/EARNINGSLOSSPERSHAREDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAttributableToParentDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss) attributable to American Renal Associates Holdings, Inc.", "totalLabel": "Net income (loss) attributable to American Renal Associates Holdings, Inc.", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CHANGESINOWNERSHIPINTERESTINCONSOLIDATEDSUBSIDIARIESDetails", "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity", "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations", "http://www.americanrenal.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r73", "r75", "r139", "r140", "r366", "r378" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Less: Net income attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToParentDiluted": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/EARNINGSLOSSPERSHAREDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.", "label": "Net Income (Loss) Attributable to Parent, Diluted", "totalLabel": "Net income (loss) attributable to common shareholders for diluted earnings per share calculation" } } }, "localname": "NetIncomeLossAttributableToParentDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r133", "r134", "r135", "r136", "r141", "r142", "r146", "r149", "r169", "r177", "r180", "r183", "r185" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income (loss) attributable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations", "http://www.americanrenal.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r127", "r128", "r129", "r130", "r131", "r132", "r135", "r153", "r196", "r197", "r198", "r199", "r200", "r201", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r343", "r344", "r345", "r346", "r472", "r473", "r474", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Accounting Pronouncements to be Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncontrolling Interest [Abstract]", "terseLabel": "Noncontrolling Interest [Abstract]" } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_NotesReceivableRelatedPartiesCurrent": { "auth_ref": [ "r59", "r121", "r452" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).", "label": "Notes Receivable, Related Parties, Current", "terseLabel": "Total amount of initial financing" } } }, "localname": "NotesReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of states the entity operates in as of the balance sheet date.", "label": "Number of States in which Entity Operates", "terseLabel": "Number of states in which company operates in" } } }, "localname": "NumberOfStatesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenseMember": { "auth_ref": [ "r392" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.", "label": "Operating Expense [Member]", "terseLabel": "Patient care costs" } } }, "localname": "OperatingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONScheduleofexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Additional operating expenses incurred related to COVID-19" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r169", "r177", "r180", "r183", "r185" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r436", "r446" ], "calculation": { "http://www.americanrenal.com/role/LEASESLeasecostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESLeasecostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r429" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r426" ], "calculation": { "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingDecember312019Details", "http://www.americanrenal.com/role/LEASESFutureMinimumLeasePaymentsUnderNoncancelableLeasesForPeriodEndingJune302020Details", "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r426" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities (Note 9)", "verboseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets", "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r426" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities, less current portion (Note 9)", "verboseLabel": "Long-term operating lease liabilities, less current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets", "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r432", "r440" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalcashflowrelatedtoleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r425" ], "calculation": { "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 }, "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "Operating lease right-of-use assets (Note 9)" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALEScheduleofassetsandliabilitiesheldforsaleDetails", "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets", "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r443", "r446" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r442", "r446" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalbalancesheetrelatedtoleasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r341" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforward" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r22", "r23", "r24", "r51" ], "calculation": { "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentDueInNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Other Commitment, to be Paid, Year One", "terseLabel": "Installment payment to be paid August 1, 2021" } } }, "localname": "OtherCommitmentDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentDueInSecondYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Other Commitment, to be Paid, Year Two", "terseLabel": "Installment payment to be paid August 1, 2022" } } }, "localname": "OtherCommitmentDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of commitment classified as other to be paid in remainder of current fiscal year.", "label": "Other Commitment, to be Paid, Remainder of Fiscal Year", "terseLabel": "Installment payment to be paid August 1, 2020" } } }, "localname": "OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r68" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Unrealized gain (loss) on derivative agreements, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax, Parent", "negatedLabel": "Unrealized pre-tax (gain) loss on derivatives" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r68", "r71" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Amounts reclassified from accumulated other comprehensive income (loss) into income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails", "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebt": { "auth_ref": [ "r31", "r490", "r508" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt classified as other.", "label": "Other Long-term Debt", "terseLabel": "Other long-term debt" } } }, "localname": "OtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r106" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other non-cash charges, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other long-term assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r87" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income - CARES Act", "verboseLabel": "Other income, CARES Act" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails", "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForLegalSettlements": { "auth_ref": [ "r102" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.", "label": "Payments for Legal Settlements", "terseLabel": "Settlement payment" } } }, "localname": "PaymentsForLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDistributionsToAffiliates": { "auth_ref": [ "r95" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.", "label": "Payments of Distributions to Affiliates", "negatedLabel": "Distributions to noncontrolling interests" } } }, "localname": "PaymentsOfDistributionsToAffiliates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r95" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Dividends and dividend equivalents paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r90" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Cash paid for acquisitions" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r91" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, equipment and intangible assets" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToMinorityShareholders": { "auth_ref": [ "r97" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.", "label": "Payments to Noncontrolling Interests", "negatedLabel": "Purchases of equity of noncontrolling interests" } } }, "localname": "PaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r294", "r318" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r20", "r42", "r43" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails", "http://www.americanrenal.com/role/REVENUEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r93" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from Debt, Net of Issuance Costs", "verboseLabel": "Proceeds from revolving credit facility and term loans, net of discounts and fees" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from divestiture of clinics" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries": { "auth_ref": [ "r89" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).", "label": "Proceeds from Divestiture of Interest in Consolidated Subsidiaries", "terseLabel": "Proceeds from sale of clinics" } } }, "localname": "ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMinorityShareholders": { "auth_ref": [ "r94" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.", "label": "Proceeds from Noncontrolling Interests", "terseLabel": "Contributions from noncontrolling interests" } } }, "localname": "ProceedsFromMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r92", "r319" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r14", "r73", "r75", "r99", "r114", "r128", "r139", "r140", "r169", "r177", "r180", "r183", "r185", "r195", "r359", "r365", "r367", "r378", "r379", "r411", "r502" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r213", "r428", "r435" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "terseLabel": "Accumulated depreciation of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r64", "r214", "r435" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property and equipment, net of accumulated depreciation of $232,711 and $215,471, respectively" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r46", "r214" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r28", "r212" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesFromStockholderMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received.", "label": "Receivables from Stockholder [Member]", "terseLabel": "Receivable from Noncontrolling Interest Holders" } } }, "localname": "ReceivablesFromStockholderMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": { "auth_ref": [ "r245", "r396" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.", "label": "Reclassifications of Temporary to Permanent Equity", "terseLabel": "Reclassification/other adjustments" } } }, "localname": "ReclassificationsOfTemporaryToPermanentEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "auth_ref": [ "r240", "r241", "r242", "r243" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "terseLabel": "Estimated redemption value" } } }, "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityFairValue": { "auth_ref": [ "r240", "r241", "r242", "r243" ], "calculation": { "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails": { "order": 1.0, "parentTag": "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.", "label": "Redeemable Noncontrolling Interest, Equity, Fair Value", "terseLabel": "Noncontrolling interests subject to put provisions stated at estimated fair value for accounting purposes" } } }, "localname": "RedeemableNoncontrollingInterestEquityFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r284", "r451", "r452" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails", "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r284", "r451", "r452", "r455" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r451" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Expense related to agreement" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r284", "r451", "r455", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails", "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r449", "r450", "r452", "r456", "r457" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r96", "r119" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "terseLabel": "Pay down of line of credit" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r96" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Payments on long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r16", "r26", "r112" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash (Note 1)" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r37", "r251", "r327", "r510", "r532", "r537" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r124", "r125", "r126", "r129", "r138", "r140", "r199", "r324", "r325", "r326", "r345", "r346", "r528", "r530" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings (Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r165", "r166", "r176", "r181", "r182", "r186", "r187", "r188", "r263", "r264", "r471" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Patient service operating revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r266", "r274" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/REVENUE" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/DEBTScheduleoflongtermdebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r441", "r446" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Finance leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalcashflowrelatedtoleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r441", "r446" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESSupplementalcashflowrelatedtoleasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r54", "r118", "r247", "r248", "r249", "r250", "r421", "r422", "r424", "r505" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of long-term debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r6", "r7", "r10", "r12", "r13", "r14", "r217", "r218" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of assets and liabilities held for sale" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/ASSETSHELDFORSALETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted earnings (loss) per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/EARNINGSLOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r293", "r315", "r329" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONScheduleofexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r293", "r315", "r329" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of maturities of long-term debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r117", "r453", "r455" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.", "label": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]", "verboseLabel": "Schedule of information concerning options activity for options to acquire common stock" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r294", "r318" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONSTOCKBASEDCOMPENSATIONAssumptionsusedforoptionsgrantedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of assumptions used for options granted to acquire common stock and the fair value at the date of grant" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock award activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "auth_ref": [ "r362", "r363", "r370", "r371", "r372", "r373", "r374", "r375", "r376" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table]", "terseLabel": "Schedule of Variable Interest Entities [Table]" } } }, "localname": "ScheduleOfVariableInterestEntitiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/VARIABLEINTERESTENTITIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r113", "r170", "r171", "r172", "r173", "r174", "r175", "r187" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeniorLienMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Legal right, before the claims of other creditors, of a creditor to possess property or other collateral in satisfaction of an outstanding debt in the event of borrower default or bankruptcy. Excludes first mortgage loans.", "label": "Senior Lien [Member]", "terseLabel": "First lien term loans" } } }, "localname": "SeniorLienMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SettledLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.", "label": "Settled Litigation [Member]", "terseLabel": "Settled Litigation" } } }, "localname": "SettledLitigationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r104" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r300" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited/Canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited/Canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r302" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r302" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested, end of period (in shares)", "periodStartLabel": "Unvested, beginning of period (in shares)", "terseLabel": "Unvested and outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested, end of period (in USD per share)", "periodStartLabel": "Unvested, beginning of period (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-average grant date fair value per award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r312" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected annual dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONSTOCKBASEDCOMPENSATIONAssumptionsusedforoptionsgrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONSTOCKBASEDCOMPENSATIONAssumptionsusedforoptionsgrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r313" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Weighted average risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONSTOCKBASEDCOMPENSATIONAssumptionsusedforoptionsgrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONSTOCKBASEDCOMPENSATIONAssumptionsusedforoptionsgrantedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Authorized additional stock options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Stock options to purchase outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r300" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited/Canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONSTOCKBASEDCOMPENSATIONAssumptionsusedforoptionsgrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r298", "r318" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options outstanding, end of period (in shares)", "periodStartLabel": "Options outstanding, beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of\u00a0options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options outstanding, end of period (in USD per share)", "periodStartLabel": "Options outstanding, beginning period (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-average exercise\u00a0price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Exercisable, end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Exercisable, end of period (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest, end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Vested and expected to vest, end of period (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Issued in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r292", "r296" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONRestrictedstockawardsDetails", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONSTOCKBASEDCOMPENSATIONAssumptionsusedforoptionsgrantedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "auth_ref": [ "r291", "r314" ], "lang": { "en-US": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-based Payment Arrangement, Employee [Member]", "terseLabel": "Employee Stock Option" } } }, "localname": "ShareBasedPaymentArrangementEmployeeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONSTOCKBASEDCOMPENSATIONAssumptionsusedforoptionsgrantedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r310", "r328" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Weighted average expected terms in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONSTOCKBASEDCOMPENSATIONAssumptionsusedforoptionsgrantedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Vested restricted stock awards withheld on net share settlement (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r437", "r446" ], "calculation": { "http://www.americanrenal.com/role/LEASESLeasecostDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESLeasecostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r58", "r124", "r125", "r126", "r129", "r138", "r140", "r156", "r199", "r246", "r251", "r324", "r325", "r326", "r345", "r346", "r413", "r414", "r415", "r416", "r417", "r418", "r528", "r529", "r530" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity", "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r124", "r125", "r126", "r156", "r471" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r32", "r33", "r246", "r251" ], "lang": { "en-US": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "negatedTerseLabel": "Forfeiture of restricted stock awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r246", "r251" ], "lang": { "en-US": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Issuance of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r32", "r33", "r246", "r251", "r299" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)", "terseLabel": "Exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity", "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONOptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r58", "r246", "r251" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r33", "r39", "r40", "r114", "r192", "r195", "r411" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total American Renal Associates Holdings, Inc. deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets", "http://www.americanrenal.com/role/CondensedConsolidatedStatementofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r114", "r124", "r125", "r126", "r129", "r138", "r195", "r199", "r251", "r324", "r325", "r326", "r345", "r346", "r357", "r358", "r377", "r411", "r413", "r414", "r418", "r529", "r530" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r439", "r446" ], "calculation": { "http://www.americanrenal.com/role/LEASESLeasecostDetails": { "order": 6.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Less: Sublease income", "terseLabel": "Rental income under subleases" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESLeasecostDetails", "http://www.americanrenal.com/role/LEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r419", "r459" ], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails", "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r419", "r459" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r419", "r459" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails", "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r419", "r459" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CERTAINLEGALANDOTHERMATTERSDetails", "http://www.americanrenal.com/role/DEBTNarrativeDetails", "http://www.americanrenal.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r458", "r460" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/SUBSEQUENTEVENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosure of Cash Flow Information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails": { "order": 1.0, "parentTag": "us-gaap_MinorityInterestChangeInRedemptionValue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of accretion of temporary equity to its redemption value during the period.", "label": "Temporary Equity, Accretion to Redemption Value", "terseLabel": "Change in estimated fair value for accounting purposes" } } }, "localname": "TemporaryEquityAccretionToRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": { "auth_ref": [], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 }, "http://www.americanrenal.com/role/EARNINGSLOSSPERSHAREDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAttributableToParentDiluted", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.", "label": "Temporary Equity, Accretion to Redemption Value, Adjustment", "negatedLabel": "Change in the difference between the redemption value and estimated fair value for accounting purposes of the related noncontrolling interests", "negatedTerseLabel": "Less: Change in the difference between the redemption value and estimated fair value for accounting purposes of the related noncontrolling interests", "terseLabel": "Additional redemption value on related noncontrolling interest" } } }, "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations", "http://www.americanrenal.com/role/EARNINGSLOSSPERSHAREDetails", "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "auth_ref": [ "r57", "r114", "r195", "r411" ], "calculation": { "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "terseLabel": "Noncontrolling interests subject to put provisions", "totalLabel": "Noncontrolling interests subject to put provisions stated at maximum redemption value" } } }, "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedBalanceSheets", "http://www.americanrenal.com/role/FAIRVALUEMEASUREMENTSScheduleoffairvaluesDetails", "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Temporary Equity Disclosure [Abstract]", "terseLabel": "Temporary Equity Disclosure [Abstract]" } } }, "localname": "TemporaryEquityDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Temporary Equity [Line Items]", "terseLabel": "Temporary Equity [Line Items]" } } }, "localname": "TemporaryEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityTableTextBlock": { "auth_ref": [ "r25", "r239" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity [Table Text Block]", "terseLabel": "Schedules of noncontrolling interests subject to put provisions" } } }, "localname": "TemporaryEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/NONCONTROLLINGINTERESTSSUBJECTTOPUTPROVISIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "Indicates type of cost from product sold and service rendered.", "label": "Cost, Product and Service [Extensible List]", "terseLabel": "Cost, Product and Service [Extensible List]" } } }, "localname": "TypeOfCostGoodOrServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "extensibleListItemType" }, "us-gaap_TypeOfRevenueExtensibleList": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Revenue, Product and Service [Extensible List]", "terseLabel": "Revenue, Product and Service [Extensible List]" } } }, "localname": "TypeOfRevenueExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "extensibleListItemType" }, "us-gaap_UnusualOrInfrequentItemAxis": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Axis]", "terseLabel": "Unusual or Infrequent Item, or Both [Axis]" } } }, "localname": "UnusualOrInfrequentItemAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualOrInfrequentItemDomain": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Domain]", "terseLabel": "Unusual or Infrequent Item, or Both [Domain]" } } }, "localname": "UnusualOrInfrequentItemDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r157", "r158", "r159", "r160", "r161", "r162", "r163" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/BASISOFPRESENTATIONORGANIZATIONANDRECENTEVENTSPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r339" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "negatedTerseLabel": "Valuation allowance released" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.", "label": "Variable Interest Entity Disclosure [Text Block]", "terseLabel": "VARIABLE INTEREST ENTITIES" } } }, "localname": "VariableInterestEntityDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/VARIABLEINTERESTENTITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Variable Interest Entity [Line Items]", "terseLabel": "Variable Interest Entity [Line Items]" } } }, "localname": "VariableInterestEntityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/VARIABLEINTERESTENTITIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "auth_ref": [ "r362", "r363", "r370", "r371", "r372" ], "lang": { "en-US": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Primary Beneficiary" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/VARIABLEINTERESTENTITIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r438", "r446" ], "calculation": { "http://www.americanrenal.com/role/LEASESLeasecostDetails": { "order": 5.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/LEASESLeasecostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r143", "r149" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "verboseLabel": "Weighted-average common shares outstanding, assuming dilution (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations", "http://www.americanrenal.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average number of common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r141", "r149" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average common shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.americanrenal.com/role/CondensedConsolidatedStatementsofOperations", "http://www.americanrenal.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r15": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2599-110228" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "16(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4549-113899" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r332": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r356": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5747-111685" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6228884-111685" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4M", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591554-111686" }, "r381": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121607252&loc=SL5864739-113975" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90193-114008" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r447": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919396-209981" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.11)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r457": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r539": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r541": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r542": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r543": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r544": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r545": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" } }, "version": "2.1" }